Food conversion is transiently affected during 4-week chronic administration of melanocortin agonist and antagonist in rats.

Jonsson L, Skarphedinsson JO, Skuladottir GV, Watanobe H, Schiöth HB

The Journal of endocrinology1 Jun 2002Cited by 43 (Europe PMC)

PMID12065241DOI10.1677/joe.0.1730517PepBankPUB-12065241

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats, MT-II-treated animals ate less than control rats during the first week of treatment.
In plain wordsIn rats, MT-II-treated animals ate less than control rats in the first week.
Peptide
Melanotan II
Outcome
DecreaseFood intake in first week
Study
ratn: not reported in source
Comparator
Control rats
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · intracerebroventricular infusion · 4 weeksAs given in this study (rat).
Source sentences
Summary
The MT-II-treated rats ate less and lost considerably more weight than the control rats during the first week of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we investigated the effect of a 4-week intracerebroventricular infusion of the melanocortin receptor agonist MT-II and the selective melanocortin-4 receptor antagonist HS024 on food intake and body weight homeostasis.
Report a problemFND-1206524101
02AnimalAnimal study (in vivo)Efficacy outcome
In rats, MT-II-treated animals lost considerably more weight than control rats during the first week of treatment.
In plain wordsIn rats, MT-II-treated animals lost more weight than control rats in the first week.
Peptide
Melanotan II
Outcome
DecreaseBody weight in first week
Study
ratn: not reported in source
Comparator
Control rats
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · intracerebroventricular infusion · 4 weeksAs given in this study (rat).
Source sentences
Summary
The MT-II-treated rats ate less and lost considerably more weight than the control rats during the first week of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we investigated the effect of a 4-week intracerebroventricular infusion of the melanocortin receptor agonist MT-II and the selective melanocortin-4 receptor antagonist HS024 on food intake and body weight homeostasis.
Report a problemFND-1206524102
03AnimalAnimal study (in vivo)Efficacy outcome
In rats, MT-II-treated animals gained weight in weeks two and three, and by the end of treatment the weight gain was similar to that of control rats.
In plain wordsIn rats, weight gain with MT-II was similar to that of control rats by the end of treatment.
Peptide
Melanotan II
Outcome
No significant changeBody weight gain by end of 4-week treatment
Study
ratn: not reported in source
Comparator
Control rats
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · intracerebroventricular infusion · 4 weeksAs given in this study (rat).
Source sentences
Summary
During the second and third week, they gained weight and, by the end of the treatment period, the weight gain was similar to that of the control rats.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we investigated the effect of a 4-week intracerebroventricular infusion of the melanocortin receptor agonist MT-II and the selective melanocortin-4 receptor antagonist HS024 on food intake and body weight homeostasis.
Report a problemFND-1206524103
04AnimalAnimal study (in vivo)Efficacy outcome
In rats, the food conversion ratio was lower in MT-II-treated animals than in controls.
In plain wordsIn rats, MT-II-treated animals gained less weight per amount of food eaten than control rats.
Peptide
Melanotan II
Outcome
DecreaseFood conversion ratio
Study
ratn: not reported in source
Comparator
Control rats
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · intracerebroventricular infusion · 4 weeksAs given in this study (rat).
Source sentences
Summary
while it was lowered in the MT-II-treated rats compared with controls.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we investigated the effect of a 4-week intracerebroventricular infusion of the melanocortin receptor agonist MT-II and the selective melanocortin-4 receptor antagonist HS024 on food intake and body weight homeostasis.
Report a problemFND-1206524104
05AnimalAnimal study (in vivo)Efficacy outcome
In rats, the MT-II effect on food conversion ratio was transient and was attenuated to the level of controls at the end of the study.
In plain wordsIn rats, the MT-II effect on weight gain per food eaten faded and matched control rats by the end.
Peptide
Melanotan II
Outcome
No significant changeFood conversion ratio at end of study
Study
ratn: not reported in source
Comparator
Control rats
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · intracerebroventricular infusion · 4 weeksAs given in this study (rat).
Source sentences
Summary
The effect on food conversion ratio was transient, being greatest for both experimental groups during the first week and it was then attenuated to reach the level of controls at the end of the study.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we investigated the effect of a 4-week intracerebroventricular infusion of the melanocortin receptor agonist MT-II and the selective melanocortin-4 receptor antagonist HS024 on food intake and body weight homeostasis.
Report a problemFND-1206524105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.